A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer
Clinical trial NCT07771764 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07771764
- Sponsor
- First Affiliated Hospital of Fujian Medical University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-01
- Primary completion
- 2029-12-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.